Omnicell (OMCL) shares have risen approximately 27% in the past month, outperforming the S&P 500; however, consensus estimates have since trended downward, shifting -46.67%. Despite a strong Growth and Value score, the stock's Momentum score is weak, and its Zacks Rank is a Hold, suggesting expectations of an in-line return in the coming months. In comparison, industry peer Hims & Hers Health (HIMS) has seen positive estimate revisions and revenue growth of 110.7% year-over-year.
Omnicell (OMCL) has experienced a significant share price increase of approximately 27% over the past month, outperforming the S&P 500. However, this rally contrasts sharply with a notable deterioration in analyst sentiment, as fresh consensus estimates for the company have declined by a substantial 46.67% during the same period. While Omnicell scores an 'A' for Growth and Value according to VGM Scores, its 'F' for Momentum suggests the recent price surge may not be well-supported by underlying technicals. The stock currently holds a Zacks Rank #3 (Hold), indicating expectations for an in-line market return in the near term, reflecting the conflicting signals of strong recent performance against weakening earnings outlook. In contrast, Hims & Hers Health (HIMS), an industry peer in the Zacks Medical Info Systems sector, has demonstrated robust fundamental strength. HIMS reported a 110.7% year-over-year revenue increase to $586.01 million in its last reported quarter (ended March 2025), with EPS growing to $0.20 from $0.05. Furthermore, HIMS's consensus estimate for the current quarter has risen by 15.6% over the last 30 days, and it carries a Zacks Rank #2 (Buy), supported by an overall VGM Score of A.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment
